in china, most blood products manufacturers mainly produce human albumin, human intravenous immunoglobulin and etc , simply because the manufacturing process of these products is relatively easy. comparing with the international peers, china’s blood products manufacturers are facing more developing bottlenecks since they are bigger in quantity but smaller in scale and lower in comprehensive utilization of plasma raw material.
the medical analyst from s&p consulting said that the concentration trend of china’s blood products industry is gradually becoming obvious. according to the health ministry’s regulation , the application condition of setting up new plasma collection stations is that: the applying company should possess at least six specifications of registered blood products, and those companies who have undertaken the task of the state planned immunization should possess at least five specifications. the result is that more than half of the blood products manufacturers could not obtain the qualifications to apply for setting up new plasma collection stations except shanghai raas, tiantan biological, china national biotec, boya bio-pharmaceutical, etc. that possibly means the acquisition and merger opportunity appears.
blood products are widely used in more and more serious diseases treatment. for example, human albumin is suitable for the treatment of post-chemical therapy or post-radiation therapy cancer patients, and human intravenous immunoglobulin can be used for the prevention and treatment of bronchial asthma, allergic skin disease, urticaria and other allergic diseases. now blood products have the irreplaceable function in clinical therapy. at the same time, the market demand also becomes bigger and bigger.
internet drug information service certificate :( shanghai) non-operating 2011-0201 卡塔尔世界杯买球入口 copyright © 2013-2014 shanghai raas all rights reserved powered by"));